EuroPCR 2024: Late-Breaking Science Video Collection

Published: 20 May 2024

  • Views:

    Views Icon 1043

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.

More from this programme

Part 1

Expert Interviews

6 sessions
Self-Expandable Vs Balloon-Expandable Valves & General Vs Local Anesthesia in TAVI: SOLVE-TAVI Watch now
Influence of Pathophysiological Patterns of CAD on PCI Watch now
Ancillary SMART Trial Analyses Watch now
Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY Watch now
TAVR Vs SAVR in Younger Low-Risk Patients with Severe Aortic Valve Stenosis: NOTION-2 Watch now
1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II Watch now

Part 2

View from the Thoraxcenter

2 sessions
View from the Thoraxcenter: What's Hot at EuroPCR 24? Watch now
View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1 Watch now

Part 3

Highlights Reviews

2 sessions
5 Trials That Will Change My Practice With Dr Mirvat Alasnag Watch now
4 Trials That Will Change My Practice with Dr Bernardo Cortese Watch now

About the episode

EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).

NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra- and post-procedural morbidity and mortality rates, hospitalization length, functional capacity, quality of life and valvular prosthesis function. Patients were randomized 1:1 to receive either TAVR or SAVR, with 186 patients in each group.

Interview Questions:

  1. What is the background of this study?
  2. What was the patient population and study design?
  3. What are the key findings?
  4. What are the implications of these findings on clinical practice? What are the main take-home messages?
  5. Where are the knowledge gaps, and what are the next steps?

Recorded onsite at EuroPCR 2024, Paris.

Editor: Jordan Rance
Video Specialist: Dan Brent,
Interviewer: Bryony Wickens

Faculty Biographies

Ole De Backer

Ole De Backer

Interventional Cardiologist

Prof Ole De Backer is an internationally renowned interventional cardiologist working at Rigshospitalet, Copenhagen University Hospital, Denmark and is an expert in structural heart interventions – among others transcatheter heart valve interventions, percutaneous left atrial appendage closure and thoracic endovascular aortic repair. Special areas of interest are the development and adoption of a fully percutaneous, minimal invasive approach for different structural heart interventions and the use of advanced cardiac imaging tools for planning and guidance of these interventions. He is actively involved and leading several research projects in the field of transcatheter heart valves and percutaneous left atrial appendage closure. 

View full profile

Comments

You must be to comment. If you are not registered, you can register here.